New Drug To Treat a Desperate Disease


Idiopathic pulmonary fibrosis (IPF)

New Drug To Treat a Desperate Disease

Author
- Dr. Gifford Jones  Sunday, January 20, 2013
| Print friendly | Email Us

Several months ago I wrote about a tennis partner who was slowly dying of idiopathic pulmonary fibrosis (IPF). We both knew there was no cure for this disease. Nor could I foresee any help for many years. I was wrong on that point. But I was right about my message of hope.

I always tell seriously ill patients the story of the man sentenced to death by the King. Because the King was a lover of horses, the man received a reprieve by promising he’d teach the King’s horse to fly within one year. His friends laughed at him, but he explained, “Within a year the King may die, I may die or the horse may die. Besides, within a year the horse may learn to fly.” The last thing to lose is hope.

Patients with IPF face a grim future. The average length of life from the time of diagnosis of IPF is usually two to five years. Fortunately, fate is occasionally kind, as some patients have lived as long as 20 years.

In some cases the course of the disease remains fairly stable. This was the case of my tennis friend. But then it became apparent that the disease was beginning to progress. During tennis games he developed a dry hacking cough, chest discomfort, but even more ominous, progressive shortness of breath along with weakness and fatigue.

IPF is associated with extensive, progressive, scarring of lung tissue. The alveoli (air sacs) in lungs begin to stiffen and become thick, decreasing the amount of oxygen in the blood stream. In effect, IPF is a slow strangulation of the body’s vital oxygen supply.

During final days any physical activity becomes an extreme effort. As my friend remarked, “It requires hours to do anything. It’s like being trapped under water and trying to surface for air.” It’s easy to understand how doctors treating these cases feel frustrated as there’s little to offer in treatment.

Sir William Olser, one of this country’s greatest physicians, felt this way when a colleague asked how he treated another difficult problem, emphysema. Osler replied, “I send these patients to Egypt”. His startled colleague asked,”Is it for the climate?” “No” Osler replied, “It’s the farthest place I can think of to send them.” It was Osler’s way of saying he had no treatment to offer them.

I had no idea when I wrote about IPF several months ago that in this short interval I’d have good news for some IPF patients. A new medication called. “Esbriet” (pirfenidone) is now available in Germany, France, Sweden, Austria, Denmark, Norway, Iceland, 27 countries in the European Union, and has just been approved by Health Canada.

Dr. Charles Chan, Professor of Medicine and Respirologist at the University of Toronto, once shared Osler’s frustration. But now he’s says “After a decade of failed clinical trials of multiple innovative drugs for IPF, Esbriet is an exciting one for IPF patients. Finally we have a treatment option with proven benefit for patients with this challenging disease.”

Esbriet is designed to fight a two-pronged attack on the underlying problems of idiopathic pulmonary fibrosis, namely the inflammation and tough scarring that eventually choke and kill lung tissue.

Esbriet accomplishes this task by decreasing the formation of cells called fibroblasts that are responsible for triggering scarring and fibrosis of air sacs in the lungs. In addition, Esbriet has an anti-inflammatory effect which helps to slow down the progression of the disease and thereby preserves exercise tolerance.

The usual dose is one oral tablet three times a day. Fortunately, Esbriet is well tolerated by most patients. A few complain of nausea, fatigue, diarrhea and heartburn.

Even if Esbriet had been available several months ago it would not have helped my friend as his IPF was too advanced at that time. But Esbriet can help to decrease the progression of those who suffer from the mild to moderate form of IPF. This is a huge step in the right direction to fight this challenging disease. And Osler would be pleased to know Egypt need no longer be an option.

Disqus Comments

W. Gifford-Jones M.D is the pen name of Dr. Ken Walker graduate of Harvard. Dr. Walker’s website is: docgiff.com.

Dr. Walker can be reached at: .(JavaScript must be enabled to view this email address).

.






Most Shared CFP stories



What's New On CFP:

  1. How to Kill the Coal Industry: Implement EPA’s “Clean Power Plan”
    By Institute for Energy Research -- --Global Warming-Energy-Environment
  2. Spouses of Guest Workers Now Eligible for Work Permits Under Obama Actions
    By News on the Net -- --News Headlines
  3. India heatwave kills 800 as capital’s roads melt
    By News on the Net -- --News Headlines
  4. APNewsBreak: IRS Says Thieves Stole Tax Info From 100,000
    By News on the Net -- --News Headlines
  5. What’s Left
    By Tabitha Korol -- --American Politics
  6. Experience the Queenstown Winter Festival
    By News on the Net -- --Vacation Resorts, Travel
  7. Wolf Trap - Act I - Habeas Corpus
    By Gary Hunt -- --American Freedom
  8. The Jihad Caucus
    By James Simpson -- --American Politics
  9. Ted Turner’s United Nations Foundation closing the gate on Free Society
    By Judi McLeod -- --Cover Story
  10. President Obama to Use the UN to Stab Israel in the Back
    By Joseph A. Klein -- --Cover Story
  11. Goodness gracious, Sir!  What happened to you?
    By Dag Barkley -- --Cartoons
  12. Josh Duggar, Atheists, and Pedophiles
    By Tim Dunkin -- --Cover Story
  13. GREAT NEWS: Appeals Court to Obama: NO, YOU CANNOT!
    By John Lillpop -- --Cover Story
  14. Here’s the Data to Prove School Choice Is Working
    By Heritage Foundation -- --News Headlines
  15. Bernie Sanders announces he would welcome the return of the 90% tax rate
    By Robert Laurie -- --American Politics
  16. Saudis gave $10 million to Clinton Foundation, then Hillary OKd an enormous Saudi arms deal
    By Dan Calabrese -- --American Politics
  17. Federal appeals court deals blow to President Obama’s amnesty
    By News on the Net -- --News Headlines
  18. Barack “Climate Change” Obama
    By Alan Caruba -- --Cover Story
  19. Biker Shootout: Libs Going Wacko over Race in Waco
    By Selwyn Duke -- --Cover Story
  20. Pelosi: We’re totally winning the war against ISIS. Y’know. On Twitter & stuff
    By Robert Laurie -- --Cover Story
  21. Why isn’t Obama demanding Iran release WaPo reporter Jason Rezaian . . .
    By Dan Calabrese -- --American Politics
  22. Saved from a world of negativity
    By Herman Cain -- --American Life, History, Education
  23. The NSA’s Technotyranny: One Nation Under Surveillance
    By John W. Whitehead -- --American Freedom
  24. The Race for the White House: What the “Invisible Primary” Has Taught Us So Far
    By INSS -- --American Politics
  25. The People vs. Santa Monica: Inside the Government’s Push to Regulate Short-Term Rental Indust
    By Heritage Foundation -- --News Headlines
  26. Why Does Liberal Rag Salon.com Hate Our Soldiers? Because They Take Money From Welfare Spending
    By Warner Todd Huston -- --Media - Media Bias
  27. Coptic Solidarity Conference - 100 Years Later: Middle Eastern Christians Face Another Genocide
    By Christian Newswire -- --Crime-Terror-Security
  28. Municipal amalgamation in Ontario fails to achieve cost savings in cities both big and small
    By Fraser Institute -- --Canada
  29. NYT: U.S. knows exactly where ISIS headquarters is, but doesn’t attack for fear of accidentally kill
    By Dan Calabrese -- --Cover Story
  30. FAA Hiring Scandal Barely Registers with the Media
    By Roger Aronoff -- --American Politics










Caruba: Professional Writing Services